Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr Marco J Haenssgen discusses the application of management thinking to solving the growing global problem of antimicrobial resistance.

Superbug

Similar stories

Gene associated with better immune response after COVID-19 vaccination identified

Researchers from the Nuffield Department of Medicine have today reported new findings from a study exploring how certain genes can help generate a strong immune response following vaccination with two commonly used COVID-19 vaccines – identifying a particular gene associated with a high antibody response.

Monkeypox can spread widely within specialist hospital isolation rooms

A new study found viral monkeypox DNA on multiple surfaces, personal protective equipment, and in air samples in hospital isolation rooms. For some of the samples, the viral particles were capable of replicating and therefore could potentially infect other people.

New computational technique reveals changes to lung function post COVID-19 infection

To investigate whether the symptoms of ‘long-COVID’ are associated with any long-term damage that reduces the function of the lungs and respiratory system, a study led by University of Oxford researchers used a novel computational approach to assess how COVID-19 may affect long-term lung function.

Malaria booster vaccine continues to meet WHO-specified 75% efficacy goal

Researchers from the NDM's Jenner Institute and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of the candidate malaria vaccine, R21/Matrix-M™ – which previously demonstrated high-level efficacy of 77% over the following 12 months in young west African children in 2021.

New monkeypox treatment trialled at Oxford University

The team behind the world-leading RECOVERY trial of COVID-19 treatments are leading a new study investigating a potential treatment for people who have been diagnosed with monkeypox. The National Institute for Health and Care Research (NIHR) has commissioned and funded the study and the first patients have now been recruited.

First clinical trial data for new rabies vaccine candidate demonstrates promising immune response and safety

Researchers from the University of Oxford have today reported new findings from a Phase 1 clinical trial studying the immune response and safety of their newly-developed single shot rabies vaccine, ChAdOx2 RabG.